Oleg Gluz, MD, Evangelical Hospital Bethesda in Moenchengladbach, Germany, addresses evolving questions in adjuvant therapy for early breast cancer. With the rapid expansion of treatment options, including chemotherapy, endocrine therapy, and newer agents like CDK4/6 inhibitors and immune therapy, the challenge lies in determining optimal combinations for different risk groups. Dr Gluz emphasizes the need to identify patients who benefit from endocrine therapy alone, those who may require additional interventions like CDK4/6 inhibitors or chemotherapy, and those who might need a more comprehensive approach. He highlights the importance of the results of the Phase II WSG-ADAPT HR+/HER- trial (NCT01779206) for high-risk HR-positive/HER2-negative early breast cancer in defining prognostic groups, guiding tailored treatments, and avoiding unnecessary interventions. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP), protected by copyright laws and treaties worldwide. All rights are reserved.
